The Global Market for Stem Cells

Report Code: BIO035E

Publish Date: Jul 2014

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2750

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

BCC Research projects that the global stem cell market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 13.6% from 2013 through 2018.

Report Includes

  • An overview of the global market for stem cells and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2018.
  • Information on the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market.
  • Examination of strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.
  • Comprehensive profiles of major players in the field.

Report Scope

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

Analyst Credentials

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the stem cell marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: The Global Market for Stem Cells169Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW8Free
Chapter- 4: STEM CELL RESEARCH28Free
Chapter- 5: STEM CELL APPLICATIONS24Free
Chapter- 6: STEM CELL PATENTS6Free
Chapter- 7: STEM CELL MARKETS43Free
Chapter- 8: C. CRAMER & CO. GMBH40Free
Chapter- 9: APPENDIX 1: GLOSSARY6Free
Chapter- 10: APPENDIX 2: SIGNIFICANT STEM CELL RESEARCH PATENTS8Free
Published - Jul-2012| Analyst - Paul Evers| Code - BIO035D

Report Highlights

The global market for stem cell products was $3.8 billion in 2011. This market is expected to reach nearly $4.3 billion in 2012 and $6.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 11.7% from 2011 to 2016.

Published - Jul-2008| Analyst - Steven Munevar| Code - BIO035C

Report Highlights

This Report:

  • The U.S. market for stem cells in regenerative medicine is expected to increase from $112.0 million in 2007 to an estimated $423.1 million by the end of 2012, a compound annual growth rate (CAGR) of 30.5%.
  • Stem cell banking was valued at $58.9 million in 2005 and $65.9 million in 2007. This is expected to rise to $155.7 million in 2012, for a CAGR of 18.8%.
  • Human adult stem cells for cell-based therapeutics were worth $21.4 million in 2006. This increased to $28.1 in 2007 and should increase to $173.8 in 2012 at a CAGR of 44.0%.
Published - Dec-2005| Analyst - Steven Edwards| Code - BIO035B

Report Highlights

  • The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate (AAGR) of 10.3%, is expected to reach $20.7 billion in 2010.
  • Nearly 98% of the market is consumed by blood and immune system treatments, a figure that will shrink slightly to 95% in 2010.
  • Revenues worldwide for stem cell, cytokine and growth factor therapies for all other bodily systems are expected to rise at an AAGR of 26.4% to just over $1 billion in 2010.
  • The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.
Published - Mar-2002| Analyst - Steven Edwards| Code - BIO035A

Report Highlights

  • Hematopoietic stem cell therapies are still the most widely used and generate the most revenue, as can be seen in the table below. We project this will remain the case through 2007, by which time over $1.3 billion in revenues will be generated by the purchase of products and services in support of these therapies. The average annual growth rate for these products, from 2001 to 2007 is expected to be 29.2%. These revenue projections, like all others in this report, exclude fees charged by physicians for their services and general hospital costs.
  • Skin, bone, and cartilage are largely derived from mesenchymal stem cells, as are tendons, ligaments, and fat cells (the epidermal layer of skin, however, comes from the ectoderm). Skin replacement to treat ulcers, burns, and surgical wounds was the first "off-the-shelf" living cell therapy to be approved. The progenitor cells for these products are fibroblasts and keratinocytes from newborn human foreskin. Chondrocytes (cartilage producing cells) are used to repair articular cartilage after knee injuries, with additional applications on the way. Combined cell and tissue engineering approaches for repairing bone fractures are being developed. In 2001, we estimate that progenitor cell therapies to replace skin, bone, or cartilage will generate about $43 million in revenues. By 2007, we expect this category to grow ten-fold to $457 million, as indicated above, for an AAGR of 48.1%.

Related Reports

Biomarkers: Technologies and Global Markets

Published - Mar 2011 | Publisher - Jackson Highsmith | Code - BIO061B

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.

Recent Reports

RNA Sequencing: Technologies and Global Markets

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO147B

The global market for RNA sequencing is expected to grow from $4.3 billion in 2024 and is projected to reach $10.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.1% during the forecast period of 2024 to 2029.

Antibody Drugs: Technologies and Global Markets

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO016M

The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.

European Life Science Tools and Reagents Market

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO262A

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 3.4% from 2024 through 2029.

Global Multiomics Market

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO260A

The global market for multiomics is expected to grow from $2.7 billion in 2024 and is projected to reach $5.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2029.

Drug Discovery Technologies

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO020H

The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.

Top Trending Reports

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

Artificial Intelligence (AI) in Life Sciences Market

Published - Aug 2024 | Publisher - BCC Publishing | Code - BIO255A

The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.

Drug Discovery Technologies

Published - Sep 2024 | Publisher - BCC Publishing | Code - BIO020H

The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.

Synthetic Biology: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - BIO066H

The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.

Electric Vehicles and Fuel Cell Vehicles: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - FCB040F

The global market for electric vehicles and fuel cell vehicles was valued at $655.9 billion in 2023. The market is expected to grow from $758.0 billion in 2024 to $1.8 trillion by 2029, at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
The Global Market for Stem Cells
Customize Report